Community Reinforcement and Family Training for Treatment Retention/HIV Risk(CDA

针对保留治疗/艾滋病毒风险的社区强化和家庭培训（CDA

• 批准号: 8118176
• 负责人: GREGORY S BRIGHAM
• 金额: $ 17.42万
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8118176
• 关键词: Agonist; Area; Behavior Therapy; Behavioral; Buprenorphine; Clinical Data; Clinical Research; Clinical Trials; Clonidine; Colorado; Communities; Development; Development Plans; Disease; Dose; Drops; Drug Addiction; Drug Metabolic Detoxication; Drug abuse; Educational Intervention; Evaluation; Family; Goals; HIV; Health; Individual; Intervention; Knowledge; Lead; Licensing; Long-Term Care; Maintenance; Maintenance Therapy; Manuals; Measures; Medical; Medical Economics; Mentors; Modeling; Ohio; Opiate Addiction; Opiates; Opioid; Outcome; Patients; Persons; Pharmaceutical Preparations; Phase; Pilot Projects; Population; Procedures; Psychological reinforcement; Public Health; Publications; Randomized; Recovery; Research; Research Personnel; Risk; Risk Behaviors; Risk Reduction; Risk Reduction Behavior; Scientist; Services; Staging; Substance Use Disorder; Supervision; Testing; Time; Training; Universities; Work; Writing; career; career development; design; effective therapy; efficacy evaluation; efficacy trial; experience; high risk; improved; induced pluripotent stem cell; man; opioid withdrawal; patient oriented; patient oriented research; primary outcome; programs; research and development; secondary outcome; social; therapy development; treatment as usual; treatment program

DESCRIPTION (provided by applicant): This K23 mentored patient-oriented research application will support the career development of the candidate in the areas of integrated behavioral and pharmacological therapies development for drug dependence treatment and long- term maintenance of recovery. Dr. Eugene Somoza of the University of Cincinnati will serve as the primary mentor. Dr. Natasha Slesnick of the Ohio State University and Dr. Robert Booth of the University of Colorado will serve as secondary mentors for behavioral therapies development and HIV risk behavior reduction respectively. In addition a team of accomplished investigators will serve as consultants to provide both training and supervision in specialized areas of the career development and research plans. The goal of the career development plan is to provide the candidate with the training and practical experience necessary to succeed as an independent investigator. The plan includes a range of mentor supervised activities including: 1) management of clinical trials, 2) publications and proposal writing, 3) attendance of graduate course work and professional seminars and, 4) the conduct of original research. The planned research will adapt a therapy of known efficacy to target a new outcome of significant importance to public health. The Community Reinforcement and Family Training (CRAFT) procedures will be adapted, from reinforcing treatment entry, to reinforcing treatment retention and HIV risk behavior reduction in persons with opioid dependence who receive a buprenorphine taper detoxification. The research plan includes three phases: 1) development of a manual guided therapy, 2) development of therapist training and fidelity measures and, 3) a randomized pilot with 52 patients receiving either the new CRAFT treatment or treatment as usual. Assessments will occur at baseline, end of treatment, 3 months and, 6 months. The primary outcome is retention in drug abuse treatment, specifically time to the opiate dependent person's first drop from services of 30 consecutive days. Secondary outcomes include: HIV risk behavior reduction, utilization of available treatment and, drug abuse. Opiate dependent individuals present a significant health risk to themselves and the public. With the recent approval of buprenorphine for drug abuse treatment, detoxification programs have become more effective at managing opioid withdrawal and transitioning patients to ongoing treatment. Following transfer to ongoing treatment retention rates decline and persons who return to opiate use are at high risk for direct negative consequences such as accidental drug over-dose and associated health risks such as HIV. Further improvements in treatment retention, maintenance of recovery and, HIV risk reduction are needed. This research and career development plan will lead to significant knowledge for improving treatment retention and reducing HIV risk behavior and, will prepare the candidate for a productive career as an independent patient-oriented clinical research scientist.

描述(由申请人提供)：这项K23指导下的以患者为导向的研究应用程序将支持候选人在药物依赖治疗和长期维持康复的综合行为和药物疗法开发领域的职业发展。辛辛那提大学的尤金·索莫扎博士将担任主要导师。俄亥俄州立大学的娜塔莎·斯莱斯尼克博士和科罗拉多大学的罗伯特·布斯博士将分别担任行为疗法开发和减少艾滋病毒风险行为的二级导师。此外，一组经验丰富的调查员将担任顾问，在职业发展和研究计划的专门领域提供培训和监督。职业发展计划的目标是为候选人提供成功成为独立调查员所需的培训和实践经验。该计划包括一系列导师监督的活动，包括：1)临床试验管理，2)出版物和提案撰写，3)参加研究生课程工作和专业研讨会，以及4)进行原创研究。这项计划中的研究将调整一种已知疗效的治疗方法，以瞄准对公共卫生具有重要意义的新结果。将调整社区强化和家庭培训(CREAT)程序，从加强治疗进入，到加强接受丁丙诺啡逐渐戒毒的阿片依赖者的治疗保留和减少艾滋病毒风险行为。研究计划包括三个阶段：1)开发手动引导疗法，2)开发治疗师培训和保真措施，3)随机试点，52名患者接受新工艺治疗或照常接受治疗。评估将在基线、治疗结束、3个月和6个月进行。主要结果是药物滥用治疗中的保留时间，特别是阿片依赖者连续30天首次停药的时间。次要结果包括：艾滋病毒风险行为的减少、现有治疗的利用和药物滥用。鸦片依赖者给自己和公众带来了巨大的健康风险。随着丁丙诺啡最近被批准用于药物滥用治疗，戒毒计划在管理阿片类药物戒断和将患者过渡到持续治疗方面变得更加有效。在转入持续治疗后，保留率下降，恢复使用鸦片类药物的人面临直接负面后果的高风险，如意外服药过量和艾滋病毒等相关健康风险。需要在保留治疗、维持康复和减少艾滋病毒风险方面进一步改进。这项研究和职业发展计划将带来改善治疗保留和减少艾滋病毒风险行为的重要知识，并将为候选人作为一名独立的、以患者为导向的临床研究科学家的富有成效的职业生涯做好准备。